Education
About Us
Working with TipRanks
Follow Us
Cybin (TSE:CYBN)
NEO-L:CYBN
CYBN Stock Chart & Stats
C$0.14
-C$0.50(-3.50%)
At close: 4:00 PM EST
C$0.14
-C$0.50(-3.50%)
Day’s Range― - ―
52-Week RangeC$0.14 - C$0.14
Previous CloseN/A
Volume13.54K
Average Volume (3M)0.00
Market Cap
C$1.92M
Enterprise ValueC$0.00
Total Cash (Recent Filing)C$116.53M
Total Debt (Recent Filing)C$40.19M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Feb 17, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)7.14
Price to Sales (P/S)0.00
P/FCF Ratio-16.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$62.51Price Target Upside44551.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And FinancingA large registered direct financing together with existing cash extends the company's runway, supporting continued clinical execution and preparation for multiple upcoming data milestones.
Clinical ReadoutsPositive Phase 2 results for lead candidate CYB003 combined with completed enrollment in the CYB004 anxiety trial increase the likelihood of favorable 2026 readouts that could re-rate the stock.
Intellectual Property And Pipeline OptionalityDevelopment of novel proprietary molecules and a diversified pipeline improves prospects for stronger intellectual property protection and differentiated commercial potential versus traditional approaches.
Bears Say
Analyst Valuation RevisionsAnalysts lowered price targets after the financing, reflecting dilution and updated modeling assumptions that compress near‑term upside.
Launch Timing And Expense NormalizationModel updates that normalize operating expenses and fine‑tune expected launch timing for lead programs reduce projected revenue assumptions and investor return expectations.
Share DilutionThe recent capital raise materially increased the share count, diluting existing holders and reducing per‑share value in investor models.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was C$0.14 and its highest was C$0.14 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is C$1.92M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Feb 17, 2026 which is in 33 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Nov 13, 2025. The company reported -C$1.947 earnings per share for the quarter, missing the consensus estimate of -C$1.455 by -C$0.492.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.81.
How many shares outstanding does Cybin have?
Currently, no data Available
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -C$1.947 in its last earnings report, missing expectations of -C$1.455. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in TSE:CYBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cybin
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CYBN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.View all TSE:CYBN earnings summariesCYBN Stock 12 Month Forecast
Average Price Target
C$62.51
▲(44551.73% Upside)
Technical Analysis
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Nirvana Life Sciences Inc
―
Mindbio Therapeutics Corp.
―
Options Prices
Currently, No data available
---